Die onkologische Supportivtherapie befasst sich mit der Vorbeugung und Behandlung von durch die onkologische Grunderkrankung und ihre Behandlung auftretenden Komplikationen. Wichtige Inhalte der onkologischen Supportivtherapie sind die Kontrolle von Infektionen, Schmerzen, Übelkeit und Erbrechen sowie Aspekte der Ernährung unter onkologischer Therapie.

Ziel der interdisziplinären Studiengruppe Onkologische Supportivtherapie ist, Fragen der onkologische Supportivtherapie in klinische Studien zu untersuchen, konform zur Guten Klinischen Praxis (Good Clinical Practice, GCP). So sollen Vorbeugung und Behandlung von Infektionen, Schmerzen sowie Übelkeit und Erbrechen verbessert und ernährungsmedizinische Aspekte der onkologischen Therapie bearbeitet werden.

Offene Klinische Studien (March 2011):

Prospective, open-label, non randomized, multicenter study to investigate the safety and tolerability of voriconazole as primary therapy for treatment of invasive aspergillosis and molds such as Scedosporium or Fusarium species in pediatric patients (Pfizer A1501080)

A prospective, open-label study to assess the pharmacokinetics, safety, and efficacy of anidulafungin when used to treat childen with invasive candidiasis, including candidemia (Pfizer A8851008)

Phase 1b Study of the Safety, Tolerance and Pharmacokinetics of Oral Posaconazole in Immuno-compromised Children with Neutropenia (Essex P03579-05)

A Multi-center, Open-label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy (MK-0869 Protocol 134)

A Phase 3, Open-Label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged (13vPnC)

Pediatric Fungal Network Invasive Fungal Infection Case Registry (Duke University, Durham, NC)

Publikationen von an unserem Zentrum durchgeführten klinischen Studien:

Cornely OA, Vehreschild JJ, Vehreschild MJGT, Würthwein G, Arenz D, Schwartz S, Heussel CP, Silling G, Mahne M, Franklin J, Harnischmacher U, Wilkens A, Farowski F, Karthaus M, Lehrnbecher T, Ullmann AJ11, Hallek M1,3, Groll AH12. A phase II dose escalation study of caspofungin for invasive aspergillosis. Clinical Infectious Diseases (submitted 02/2011) Würthwein G, Young C, Lanvers-Kaminsky C, Hempel G, Schwerdtfeger R, Ostermann H, Heinz WJ, Cornely OA, Kolve H, Boos J, Silling G and Groll AH. Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients. Antimicrobial Agents Chemother (submitted 02/2011) Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, Jafri H, Arrieta AC, Klein NJ, Lutsar I. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010 Oct;54(10):4116-23. Groll AH, Silling G, Young C, Schwerdtfeger R, Ostermann H, Heinz WJ, Gerss J, Kolve H, Lanvers-Kaminsky C, Vieira Pinheiro JP, Gammelin S, Cornely OA, Wuerthwein G. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother. 2010 Oct;54(10):4143-9 Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS, Green M, Nania JJ, Bourque MR, Wise BA, Strohmaier KM, Taylor AF, Kartsonis NA, Chow JW, Arndt CA, DePauw BE, Walsh TJ; Caspofungin Pediatric Study Group.  A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J. 2010 May;29(5):415-20. Meisel R, Kuypers L, Dirksen U, Schubert R, Gruhn B, Strauss G, Beutel K, Groll AH, Duffner U, Blütters-Sawatzki R, Holter W, Feuchtinger T, Grüttner HP, Schroten H, Zielen S, Ohmann C, Laws HJ, Dilloo D; Impfung von Kindern nach allogener Stammzelltransplantation (IKAST) Study Group. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2007 Mar 15;109(6):2322-6. Würthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother. 2005 Dec;49(12):5092-8.